research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
Search
for
Sort by
Research
30 / 489 resultsresearch Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
research Under Development JAK Inhibitors for Dermatologic Diseases
New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
Albizia saponaria bark extract may help treat hair loss.
research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
research Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
Urban air pollution worsens hair loss in alopecia areata by increasing immune response.
research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Ritlecitinib may help treat alopecia areata by protecting hair follicles.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
research 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
Kaempferol promotes hair growth and could be a natural treatment for hair loss.
research Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
research 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.